Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Cogan

Clinical Cardiac Electrophysiology Hollywood, FL Medical Doctor

NPI 1841247558 CMS profile 129165

1150 N 35Th Ave, Suite 605, Hollywood, FL 33021

Open in the dashboard

General payments

$39,132

145 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Cogan of Hollywood, FL is reported in the CMS Open Payments database as having received $39,132 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,881 44
2024 General $3,903 13
2023 General $2,191 21
2022 General $1,030 10
2021 General $7,603 14
2020 General $6,122 19
2019 General $9,402 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Cogan
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to John Cogan were reported at $8,881. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year John Cogan Clinical Cardiac Electrophysiology median Middle half National median
2019 $9,402 $2,361 $585–$8,260 $163
2020 $6,122 $993 $247–$4,351 $114
2021 $7,603 $1,185 $326–$4,739 $132
2022 $1,030 $2,073 $554–$6,789 $149
2023 $2,191 $2,568 $759–$8,159 $160
2024 $3,903 $2,557 $703–$7,403 $164
2025 $8,881 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $20,862 68 payments
  2. Medical Device Business Services, Inc. $8,125 5 payments
  3. Biosense Webster, Inc. $6,321 16 payments
  4. Boston Scientific Corporation $1,854 25 payments
  5. Medtronic, Inc. $1,503 13 payments
  6. Philips Electronics North America Corporation $161 4 payments
  7. Biotronik Inc. $86 1 payment
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $63 3 payments
  9. Abiomed $34 2 payments
  10. Baxter Healthcare $30 2 payments
  11. Other $94 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $24,115 11 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,634 7 payments
  3. Food and Beverage $5,094 105 payments
  4. Travel and Lodging $4,290 22 payments
Products named General payments · program years 2019–2025
  1. Carto 3 System $9,012 20 payments
  2. Accent Pacemaker $6,640 2 payments
  3. Quadra Allure MP RF CRT Pacemkr $5,634 7 payments
  4. Carto 3 $5,519 2 payments
  5. ENSITE Electrophysiology $3,423 3 payments
  6. AVEIR Structural Heart $1,639 15 payments
  7. AVEIR Cardiac Rhythm Management $934 8 payments
  8. ENSITE Structural Heart $490 2 payments
  9. EVERA MRI XT DR SURESCAN $440 6 payments
  10. Advisor Catheter $330 2 payments
  11. Other $3,209 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

817

Median for Cardiology: 2,533

Drug cost

$290,644

Median for Cardiology: $485,213

Branded share of claims

41.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 192 $198,828
Multaq Dronedarone Hcl Brand 72 $59,681
Xarelto Rivaroxaban Brand 22 $16,414
Entresto Sacubitril/Valsartan Brand 13 $8,777
Metoprolol Succinate Generic 82 $1,142
Amiodarone Hcl Generic 47 $933
Digoxin Generic 49 $876
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 27 $807
Metoprolol Tartrate Generic 108 $681
Flecainide Acetate Generic 25 $681

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$132,515

Medicare's payments for the services billed

Medicare patients

1,039

Average age 79

Services billed

2,233

482 women, 557 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 60%
Ischemic heart disease 58%
Chronic kidney disease 50%
Heart failure 49%
Arthritis 48%
Diabetes 43%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record